Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03732820 · ClinicalTrials.gov registry record · Phase 3

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

A Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
895
Enrollment target
20
Study locations

NCT03732820 is a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 895 participants, above the 185-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (384% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03732820, a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
895 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG abiraterone acetate
  • DRUG olaparib

Study Locations (20)

California

  • Research Site - Clovis
  • Research Site - Los Angeles
  • Research Site - Los Angeles
  • Research Site - Sacramento
  • Research Site - San Diego

Arizona

  • Research Site - Tucson
  • Research Site - Tucson

Michigan

  • Research Site - Detroit
  • Research Site - Grand Rapids

Alabama

  • Research Site - Birmingham

Alaska

  • Research Site - Anchorage

Colorado

  • Research Site - Denver

Illinois

  • Research Site - Lisle

Indiana

  • Research Site - Jeffersonville

Trial Details

FieldValue
Enrollment Target 895 participants
Start Date 2018-10-31
Est. Completion 2026-04-27
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03732820

The ClinicalTrials.gov registry entry for NCT03732820 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 895 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 185-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (384% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which abiraterone acetate is the first listed.

NCT03732820 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Arizona, Michigan.

Frequently Asked Questions

What is clinical trial NCT03732820 about?

NCT03732820 is a clinical study titled "Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer". The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or...

What is the current status of trial NCT03732820?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 895 participants. The study started on 2018-10-31. Estimated completion is 2026-04-27.

What conditions does trial NCT03732820 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT03732820?

The interventions under investigation include: abiraterone acetate (DRUG), olaparib (DRUG).

Who is sponsoring clinical trial NCT03732820?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03732820 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.